Statera Biopharma, Inc. Common Stock
STAB
STAB was delisted on the 11th of January, 2023.
14 hedge funds and large institutions have $242K invested in Statera Biopharma, Inc. Common Stock in 2019 Q4 according to their latest regulatory filings, with 1 funds opening new positions, 4 increasing their positions, 3 reducing their positions, and 4 closing their positions.
33% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 3
0.44% less ownership
Funds ownership: 3.99% → 3.55% (-0.44%)
18% less funds holding
Funds holding: 17 → 14 (-3)
75% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 4
90% less capital inflows, than outflows
Capital inflows: $4.89K | Capital outflows: $50K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$2.59K |
| 2 |
Bank of America
Charlotte,
North Carolina
|
+$2.09K |
| 3 |
B. Riley Wealth Advisors
Boca Raton,
Florida
|
+$203 |
| 4 |
Barclays
London,
United Kingdom
|
+$13 |
| 5 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$1 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$29K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$13.4K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$5.26K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$1K |
| 5 |
Victory Capital Management
San Antonio,
Texas
|
-$1K |
STAB Hedge Fund Activity: Q4 2019 in Review
14 of the 5,094 institutional investors tracked by Wall St. Rank reported a position in Statera Biopharma, Inc. Common Stock (STAB) for Q4 2019, worth a combined $242K — down 47% from $456K a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of STAB and 1 opened new positions — a net loss of 3 holders — while 3 trimmed existing stakes and 4 added.
The largest buyer was Renaissance Technologies, adding an estimated $2.59K. The largest seller was Citadel Advisors, exiting entirely with an estimated $29K sold.
- 14 institutional investors held Statera Biopharma, Inc. Common Stock (STAB) as of Q4 2019, down from 17 in Q3 2019.
- Funds reported $242K of Statera Biopharma, Inc. Common Stock stock for Q4 2019, down 47% quarter-over-quarter.
- 1 fund opened new Statera Biopharma, Inc. Common Stock positions in Q4 2019 and 4 closed out, a net change of -3 holders.
- The largest Statera Biopharma, Inc. Common Stock buyer in Q4 2019 was Renaissance Technologies, an estimated $2.59K added.
- The largest Statera Biopharma, Inc. Common Stock seller in Q4 2019 was Citadel Advisors, an estimated $29K sold.
Based on aggregated 13F filings for Q4 2019.